"EuBiologics expected to rebound in Q3 earnings"
Predicted impact: Low
Analyst expects Q3 rebound; forecast only, no reported figures.
EuBiologics유바이오로직스
206650 · KOSDAQ · ₩206650 · 유바이오로직스
₩7,620▲ ₩120 (1.60%)End-of-day · Oct 28, 2026 · End-of-day prices.
EuBiologics Signs ₩10.5B Vaccine Supply Contract with UNICEF
Predicted impact: Low
₩10.5B UNICEF contract is about 9% of last year's revenue, but near 10% threshold and modest.
WHO Director-General visits Yoobiologics, reviews global vaccine capabilities
Predicted impact: Low
WHO official visit with no immediate financial impact.
YuBioLogics announces Phase 1 results for shingles vaccine clinical trial; submits IND application for Phase 2 trial
Predicted impact: Medium
Phase 1 shingles vaccine results are meaningful pipeline progress but early-stage and not yet commercial revenue.
Also known as: EuBiologics / 유바이오로직스 / 206650 / KRX:206650
Source: KRX statistical information